University of Zürich
7th in Switzerland
2nd in Switzerland
2nd in Switzerland
5th in Switzerland
Journal Editors at University of Zürich
Reviewers from University of Zürich
Prof. Günther Hofbauer holds an M.D. degree. Prof. Hofbauer is a dermatologist and allergist/clinical immunologist, trained at the University Hospital Zürich, Switzerland. He went to medical school in Switzerland (Basel, Lausanne) and Germany (Heidelberg). Prof. Hofbauer has completed a postdoctoral fellowship at the Dermatology Branch, National Cancer Institute, National Institutes of Health. He is the Head of the SGDV Working Group for dermatology and organ transplantation and was the President of SCOPE, a European association of dermatologists caring for organ transplant recipients. Prof. Hofbauer previously worked as physician, latest position held Senior Staff Physician, at the University Hospital Zurich, Switzerland. He now practices dermatology, allergy and clinical immunology at Allderm in Wetzikon, serves as counsel at Hirslanden hospital in Zürich and is primary investigator at the University of Zürich, Department of Dermatology. His lab at Zürich University holds a strong research interest in squamous cell carcinoma of the skin and potential prevention and treatment.
Karl Gademann is a full professor for organic chemistry and chemical biology at the University of Zürich.
Karl Gademann (1972) was educated at ETH Zürich and Harvard University, where he worked with Prof. Dieter Seebach, Prof. Eric N. Jacobsen, and Prof. Erick M. Carreira. His previous professorial appointments include the EPFL in Lausanne and the University of Basel, where he served as full professor and dean of research. He has been elected to the board of the Swiss Academy of Sciences, and is affiliated to the NCCR Chemical Biology and the NCCR Molecular Systems Engineering. In Summer 2015, Karl Gademann moved to the University of Zürich.
His work has been recognized by a number of international awards, including the Latsis prize, the Novartis Early Career Award, the Ruzicka Medal, The Liebig Lecture by the German Chemical Society, and the European Young Investigator Award. He delivered the Novartis Chemistry Lecture at the University of Illinois in 2016.
Deputy Head of Radiology at the Orthopedic University Hospital Balgrist in Zurich/Switzerland.
Main research interests: Imaging of the joints, imaging of metal hardware and reduction of metal artifacts at MR and CT. PD Dr. Reto Sutter published several seminal studies on femoroacetabular impingement and on metal artifact reduction. Before coming to Balgrist University Hospital, Dr Sutter worked in radiology and pathology in the University Hospital Zurich/Switzerland and the cantonal hospital in Winterthur/Switzerland as well as in the Royal London Hospital/Queen Mary University in London/UK. Dr Sutter is a senior lecturer (Privatdozent) at the Medical Faculty of the University of Zurich.
Associate editor of Psychotherapy Research Associate editor of APA-journal of Psychotherapy Integration Editorial board of APA-journal of Counseling Psychology Editorial board of APA Psychotherapy Editorial board of Psychotherapie, Psychosomatik, Medizinische Psychologie (PPmP) Coeditor of Psychotherapie im Dialog (PiD)
Since 2014 Dr Gregor Berger leads the developmental psychopharmacology research group of the Clinic of child and adolescent psychiatry, University of Zürich, Switzerland. Clinically he is responsible for the psychiatric emergency service of the department of child and adolescent psychiatry Zürich, Switzerland. From 2010 to 2014 Dr. Berger was the head of the adolescent psychiatric services of the integrated psychiatry Winterthur, From 2009-2010 he worked as a senior consultant at the Cliena Schlössli AG. From 2006-2007 he worked as a consultant in the Department of Psychiatry at the University Hospital Basel. From 1999 to 2006 Dr. Berger lived in Melbourne, Australia and worked at the University of Melbourne, where he established the Unit for Neuroprotection in Young People (UNYP) at ORYGEN Research Centre encompassing the Early Psychosis Prevention and Intervention Centre (EPPIC). In 2004 he had the opportunity to spend six months at the Clinical Brain Disorders Branch at the National Institute of Mental Health with Dr Daniel Weinberger’s group.
Dr Gregor Berger was awarded a Young Investigator Award from the Swiss National Science Foundation to pursue his work examining the importance of omega-3 fatty acids (eicosapentaenoic acid) in early psychosis. This first project, which is completed, has used a neuroprotective oil called ethyl-eicosapentaenoic acid (that inhibits one of the key enzymes of the natural cell death program) as an add-on therapy in 80 patients with a first episode psychosis. He further received a Stanley Medical Research Centre award together with Assoc. Professor Paul Amminger to investigate fish oil in ultra-high risk patients, as well as a NHMRC project grant (ID 209062) to measure in vivo brain lipid metabolism using phosphorus magnetic resonance spectroscopy in early psychosis and correlating the findings with gene variations of key-lipid candidate genes. He further received a grant form the Stanley Medical Research Centre to investigate the neuroprotective effects of low-dose lithium in patients at ultra-high risk for psychosis. Finally he received a major investigator initiated grant from Astra Zeneca to do a quetiapine dose finding study in 150 first episode psychosis patients. Recently he received a Swiss National Science IICT grant to investigate the effects of Omega-3 fatty acids in children and adolescents with a major depressive disorder.